Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch sold 400 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $60.00, for a total value of $24,000.00. Following the sale, the director now owns 130,544 shares of the company’s stock, valued at $7,832,640. The trade was a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Daniel Lynch also recently made the following trade(s):

• On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $54.46, for a total value of $9,530,500.00.

SpringWorks Therapeutics Trading Down 1.0 %

NASDAQ SWTX opened at $55.73 on Thursday. The business’s 50-day moving average price is $40.27 and its two-hundred day moving average price is $37.31. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $60.00.

Institutional Trading of SpringWorks Therapeutics

Several institutional investors have recently added to or reduced their stakes in SWTX. GF Fund Management CO. LTD. acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter worth approximately $56,000. Palisades Investment Partners LLC raised its stake in SpringWorks Therapeutics by 9.9% during the fourth quarter. Palisades Investment Partners LLC now owns 134,445 shares of the company’s stock worth $4,857,000 after buying an additional 12,154 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in SpringWorks Therapeutics by 19.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,052 shares of the company’s stock valued at $4,301,000 after buying an additional 19,315 shares during the period. Woodline Partners LP boosted its position in SpringWorks Therapeutics by 7.9% during the fourth quarter. Woodline Partners LP now owns 1,490,136 shares of the company’s stock valued at $53,839,000 after acquiring an additional 108,512 shares during the last quarter. Finally, Zimmer Partners LP acquired a new stake in SpringWorks Therapeutics during the 4th quarter worth about $5,141,000.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on SWTX shares. Evercore ISI upped their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a report on Monday, February 10th. Finally, Guggenheim cut their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $70.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.